3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
36
Carcinoma, Non-Small-Cell Lung
17
Small Cell Lung Carcinoma
16
Neoplasms
14
Lung Neoplasms
13
Breast Neoplasms
8
Melanoma
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Prostatic Neoplasms
5
Liver Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Glioblastoma
4
Endometrial Neoplasms
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Neoplasms by Histologic Type
3
Carcinoma, Transitional Cell
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Small Cell Lung Cancer Extensive Stage
2
Sarcoma, Alveolar Soft Part
2
Osteosarcoma
2
Mesothelioma, Malignant
2
Mesothelioma
2
Interventions
Bevacizumab
4
Paclitaxel
2
Lutetium-177
2
Lutetium
2
ribociclib
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
camrelizumab
1
atezolizumab
1
apatinib
1
Tretinoin
1
Radiation
1
Propranolol
1
Leucovorin
1
Irinotecan
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Digestive System Neoplasms
×
atezolizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled